TESSA THERAPEUTICS LTD
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Tessa Therapeutics Announces Enrollment of 12 Patient Pilot Cohort in its Relapsed or Refractory Hodgkin Lymphoma Phase 2 Study 2021-04-30 18:00
Tessa Therapeutics Announces Successful Dosing of First Patient Cohort in Phase I Allogeneic Cell Therapy Trial 2021-02-10 19:51
Tessa Therapeutics Announces Successful Dosing of First Patient Cohort in Phase I Allogeneic Cell Therapy Trial 2021-02-10 19:12
Tessa Therapeutics Receives PRIME Designation from European Medicines Agency for CD30 CAR-T Therapy 2021-01-18 19:00
Tessa Therapeutics Appoints David McIntyre as Chief Financial Officer 2020-12-17 22:32
Tessa Therapeutics Announces Results from Two Independent Phase 1/2 Trials of Autologous CD30 CAR-T Cell Therapy in Patients with Relapsed or Refractory Hodgkin Lymphoma 2020-08-06 19:00
Tessa Therapeutics Announces New Executive Leadership 2020-05-05 00:00
Tessa Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to its CD30 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory CD30-positive Classical Hodgkin Lymphoma 2020-02-27 20:00
Tessa Therapeutics to Open 90,000 Square Foot Commercial-Scale Cell Therapy Manufacturing Facility in Singapore in 2020 2019-12-19 20:00
Tessa Therapeutics and China-Singapore Guangzhou Knowledge City Form Landmark US$120 Million Joint Venture in China to Develop Innovative Cell Therapies for Cancer 2019-06-13 07:15
Tessa Therapeutics, in Collaboration with Baylor College of Medicine, Presents Preclinical Results Showing Enhanced T Cell Responses Against HER2-Positive Solid Tumors Using Novel Combination CAR T Cell Therapy 2019-04-30 22:00
Tessa Therapeutics Announces Collaboration with MSD Investigating the Combination of KEYTRUDA® (pembrolizumab) and Virus-Specific T Cell Therapy Targeting Human Papillomavirus in Cervical Cancer 2019-04-16 07:15
Tessa Therapeutics Announces Collaboration with Merck Investigating the Combination of KEYTRUDA® (pembrolizumab) and Virus-Specific T Cell Therapy Targeting Human Papillomavirus in Cervical Cancer 2019-04-16 07:15
Tessa Therapeutics Names Biopharma Veteran Jeffrey H. Buchalter to Board of Directors 2019-03-01 07:15
Distinguished Breast Cancer Expert, Dr. George W. Sledge, Jr., M.D., to join the Board of Tessa Therapeutics 2018-12-21 09:18
St. Jude Children's Research Hospital and Tessa Therapeutics Announce Strategic Collaboration 2018-09-21 08:28
Tessa Therapeutics announces new Board Member and increase of recent funding round 2018-04-12 07:03
Tessa Therapeutics Announces Opening of Recruitment Sites Across the United States for its Phase III Nasopharyngeal Cancer Immunotherapy Trial 2018-02-06 07:00
Tessa Therapeutics Closes USD 80 Million Financing Round Led by Temasek 2017-12-20 06:00
1